Immuron’s New Oral Therapeutic Shows Promise in NMRC Trial

Immuron Limited (AU:IMC) has released an update.

Immuron Limited reports that the US Naval Medical Research Command (NMRC) has completed an interim analysis of a clinical trial evaluating a new oral therapeutic produced by Immuron against enteric pathogens. The study showed a 10.4% effectiveness in preventing moderate to severe campylobacteriosis, with further data analysis ongoing. Findings will be presented at an international workshop, as Immuron continues its collaboration on hyperimmune products with NMRC.

For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.